Immunofoco Biotechnology

Shanghai, China · Founded 2020 · In IPO Registration

Developer and manufacturer of CAR-T cell therapies and innovative treatment platforms designed for solid tumors and hematological cancers. Immunofoco Biotechnology is based in Shanghai, China and was founded in 2020. Its last reported valuation was $298 million in Feb 2026. It has raised $139 million.

Last reported valuation

$298.1M

Oct 2026

Priced at

—

Total raised

$138.8M

Last round

—

How much has Immunofoco Biotechnology raised?

$138.8Macross 0 recorded rounds

Free account

More of Immunofoco Biotechnology with a free account

·The complete investor list: 27 names
·Watch Immunofoco Biotechnology: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Immunofoco Biotechnology investors

27 investors are on record for Immunofoco Biotechnology, including ZhenFund, Green Pine Capital Partners, Shenzhen Nanshan Strategic Emerging Industry Investment and Orinno Capital. By type, the record holds 5 venture capital firms.

For fundraisers

Raising for a company like Immunofoco Biotechnology?

27 investors have backed Immunofoco Biotechnology.

See all 27 investors →

Frequently asked about Immunofoco Biotechnology

How much has Immunofoco Biotechnology raised?: Immunofoco Biotechnology has raised $138.8M in total across 0 recorded funding rounds.